KR102795692B1 - 키메라 항원 수용체를 발현하는 조절 t 세포 - Google Patents

키메라 항원 수용체를 발현하는 조절 t 세포 Download PDF

Info

Publication number
KR102795692B1
KR102795692B1 KR1020207022067A KR20207022067A KR102795692B1 KR 102795692 B1 KR102795692 B1 KR 102795692B1 KR 1020207022067 A KR1020207022067 A KR 1020207022067A KR 20207022067 A KR20207022067 A KR 20207022067A KR 102795692 B1 KR102795692 B1 KR 102795692B1
Authority
KR
South Korea
Prior art keywords
cells
car
antigen
treg
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022067A
Other languages
English (en)
Korean (ko)
Other versions
KR20200113211A (ko
Inventor
안나 노박
도미니트 로크
안드류 카이저
알렉산더 쉐폴드
Original Assignee
밀테니 비오텍 비.브이. & 씨오. 케이지
샤리떼 우니베지테츠메디친 베를린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밀테니 비오텍 비.브이. & 씨오. 케이지, 샤리떼 우니베지테츠메디친 베를린 filed Critical 밀테니 비오텍 비.브이. & 씨오. 케이지
Publication of KR20200113211A publication Critical patent/KR20200113211A/ko
Application granted granted Critical
Publication of KR102795692B1 publication Critical patent/KR102795692B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207022067A 2018-01-19 2019-01-17 키메라 항원 수용체를 발현하는 조절 t 세포 Active KR102795692B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18152631 2018-01-19
EP18152631.0 2018-01-19
PCT/EP2019/051143 WO2019141774A1 (en) 2018-01-19 2019-01-17 Regulatory t cell expressing a chimeric antigen receptor

Publications (2)

Publication Number Publication Date
KR20200113211A KR20200113211A (ko) 2020-10-06
KR102795692B1 true KR102795692B1 (ko) 2025-04-16

Family

ID=61027458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207022067A Active KR102795692B1 (ko) 2018-01-19 2019-01-17 키메라 항원 수용체를 발현하는 조절 t 세포

Country Status (8)

Country Link
US (1) US12178872B2 (https=)
EP (1) EP3740569B1 (https=)
JP (1) JP7720148B2 (https=)
KR (1) KR102795692B1 (https=)
CN (1) CN111684061B (https=)
CA (1) CA3088832A1 (https=)
ES (1) ES2960686T3 (https=)
WO (1) WO2019141774A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019141774A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
AU2020333659A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Anti-CD83 chimeric antigen receptor expressing t regulatory cells
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
WO2021156277A1 (en) * 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
WO2021183687A2 (en) 2020-03-10 2021-09-16 Cellares Corporation Systems, devices, and methods for cell processing
CA3259305A1 (en) * 2022-07-11 2024-01-18 Sonoma Biotherapeutics, Inc. RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE
US12180453B2 (en) 2023-03-21 2024-12-31 Cellares Corporation Systems, devices, and methods for electroporation within a cell processing system
US12399193B2 (en) 2023-05-05 2025-08-26 Cellares Corporation Systems, devices, and methods for combined cell processes
EP4467155A1 (en) * 2023-05-23 2024-11-27 Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIBHGM) Car-thytreg cells, compositions and uses thereof in immunotherapy
WO2025007051A2 (en) 2023-06-30 2025-01-02 Cellares Corporation Systems, devices, and methods for fluid transfer within an automated cell processing system
WO2025041064A2 (en) 2023-08-21 2025-02-27 Cellares Corporation Systems, devices, and methods for automatic cell sorting
US12305156B2 (en) 2023-08-21 2025-05-20 Cellares Corporation Systems, devices, and methods for fluid control in a cell processing system
US12497587B2 (en) 2023-08-21 2025-12-16 Cellares Corporation Bioreactors and methods of their use in automatic cell processing systems
US12492368B2 (en) 2024-03-11 2025-12-09 Cellares Corporation Monitoring air pressure within a cell processing system
WO2025202944A2 (en) 2024-03-27 2025-10-02 Cellares Corporation Liquid level and flow rate detection within a cell processing system
USD1109621S1 (en) 2024-04-15 2026-01-20 Cellares Corporation Analytical platform for biological material testing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100428A1 (en) 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
DE102009040716B4 (de) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
CN102153651B (zh) 2011-01-21 2012-11-14 厦门大学 抗葡聚糖单链抗体及其制备方法
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
JP2018527932A (ja) 2015-09-07 2018-09-27 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ＣＤ８＋ＣＤ４５ＲＣｌｏｗ Ｔｒｅｇの新しい亜集団およびその使用
PL3368571T3 (pl) 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
JP2019508036A (ja) 2016-02-16 2019-03-28 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫療法組成物及び方法
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
US20170274095A1 (en) * 2016-03-23 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN107557342A (zh) 2017-11-02 2018-01-09 广东万海细胞生物科技有限公司 一种CAR‑Treg 细胞的制备方法及其应用
WO2019141774A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
CN117693439A (zh) 2021-07-28 2024-03-12 伊顿智能动力有限公司 自适应可控车辆逆变器系统和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100428A1 (en) 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Boardman DA. et al., American Journal of Transplantation (2017) 17(4):931-943
MacDonald KG et al. Journal of Clinical Investigation (2016) 126(4):1413-1424
McGovern JL et al. Frontiers in Immunology (2017) 8:1517

Also Published As

Publication number Publication date
US20200353004A1 (en) 2020-11-12
EP3740569B1 (en) 2023-07-26
CA3088832A1 (en) 2019-07-25
JP2021511041A (ja) 2021-05-06
EP3740569A1 (en) 2020-11-25
ES2960686T3 (es) 2024-03-06
KR20200113211A (ko) 2020-10-06
CN111684061B (zh) 2024-07-30
CN111684061A (zh) 2020-09-18
WO2019141774A1 (en) 2019-07-25
JP7720148B2 (ja) 2025-08-07
US12178872B2 (en) 2024-12-31

Similar Documents

Publication Publication Date Title
KR102795692B1 (ko) 키메라 항원 수용체를 발현하는 조절 t 세포
US20220281944A1 (en) Spycatcher and spytag: universal immune receptors for t cells
JP7047172B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US11299536B2 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
JP2023029373A (ja) キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
KR102742220B1 (ko) 항-hla-a2 항체 및 그 사용 방법
US20190330300A1 (en) Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
JP2021534802A (ja) 複数のｈｌａ−ｇアイソフォームに対するキメラ抗原レセプター
CN112771154B (zh) 含有nef的t细胞及其产生方法
JP2019531056A (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CA3098865A1 (en) Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
JP2019513394A (ja) キメラアロ抗原受容体ｔ細胞の組成物および方法
JP2021526795A (ja) 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
US20220242931A1 (en) Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells
US20220096547A1 (en) Modified immune cells expressing flagellin polypeptide
RU2782276C2 (ru) Анти-hla-a2 антитела и способы их применения
CA3154589A1 (en) Compositions and methods for switchable car t cells using surface-bound sortase transpeptidase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200729

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220114

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241017

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250407

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250409

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250409

End annual number: 3

Start annual number: 1

PG1601 Publication of registration